(Q46565350)

23 December 2017

title

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial (English)

1 reference

23 December 2017

1 reference

restless legs syndrome

1 reference

1

Claudia Trenkwalder

1 reference

PubMed ID

18515185

23 December 2017

Karin Stiasny-Kolster

10

Karin Stiasny-Kolster

1 reference

23 December 2017

Markku Partinen

Markku Partinen

13

0 references

Kallol Ray Chaudhuri

K Ray Chaudhuri

12

0 references

Birgit Högl

11

Birgit Högl

1 reference

23 December 2017

7

Luigi Ferini-Strambi

1 reference

23 December 2017

3

Werner Poewe

1 reference

23 December 2017

4

Wolfgang H Oertel

1 reference

23 December 2017

9

Per Odin

1 reference

23 December 2017

2

Heike Benes

1 reference

23 December 2017

Ralf Kohnen

15

Ralf Kohnen

1 reference

23 December 2017

author name string

Diego Garcia-Borreguero

5

1 reference

23 December 2017

Al W de Weerd

6

1 reference

23 December 2017

Pasquale Montagna

8

1 reference

23 December 2017

Erwin Schollmayer

14

1 reference

23 December 2017

SP790 Study Group

16

1 reference

23 December 2017

publication date

1 July 2008

1 reference

23 December 2017

published in

Lancet Neurology

1 reference

23 December 2017

volume

7

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

page(s)

595-604

1 reference

23 December 2017

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

A genetic risk factor for periodic limb movements in sleep

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Burden of restless legs syndrome on health-related quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

The restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Augmentation of the restless legs syndrome with carbidopa/levodopa.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Augmentation as a treatment complication of restless legs syndrome: concept and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Sex and the risk of restless legs syndrome in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

Efficacy and safety of pramipexole in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970112-1

7 January 2021

10.1016/S1474-4422(08)70112-1

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

18515185

1 reference

23 December 2017